Effects of Probiotics on Neonatal Hyperbilirubinemia

Karadeniz Technical University150 enrolled

Overview

This study was designed as a prospective controlled study to investigate the effects of probiotic support started immediately after birth on newborn jaundice in breastfed babies born by normal spontaneous vaginal delivery.

Objectives: Enterohepatic circulation of bilirubin imposes an extra burden of approximately 30% on total serum bilirubin levels. Intestinal microflora is the main factor affecting enterohepatic circulation. This study investigated the effects of probiotic support started immediately after birth on neonatal hyperbilirubinemia in babies born by normal spontaneous vaginal delivery and breastfed only. Methods: A total of 150 healthy term newborns were included in the study and allocated in the study and control groups. Immediately after birth, newborns in the study group received probiotic in liquid drop form (Maflor® drops containing Lactobacillus Rhamnosus GG 109 Colony Forming Units(CFU), Mamsel Pharmaceuticals, Turkey), at a dose of 5 drops a day orally for 10 days. Newborns in the control group received 5 drops of saline solution per day orally, instead. In addition to routine biochemical examinations;serum bilirubin levels in the cord blood, and blood samples of the newborns on the 3rd, 5th and 10th days of birth were measured in all subjects in both groups. Defecation frequency was recorded for all subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

150

Conditions

Neonatal Hyperbilirubinemia

Interventions

Maflor®, Mamsel Pharmaceuticals, TurkeyBIOLOGICAL

Dietary Supplement: Probiotics probiotics at a dose of 1x109 CFU/day. (Maflor®, Lactobacillus rhamnosus GG 109 CFU, Mamsel Pharmaceuticals, Turkey) Other Name: Maflor®

drops of salineOTHER

Dietary Supplement: Breast milk +drops of saline

Eligibility

Sex: ALLMin age: 1 DayMax age: 10 DaysHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * A total of 150 full-term (gestational age ≥37 - \<42 weeks) normal spontaneous vaginal delivery healthy newborns * Birth weight between the 10th-90th percentiles * Fed by breast milk only Exclusion Criteria: * Newborns with familial hematologic disorders * Having signs of hemolysis due to blood group incompatibilities * Bleeding into closed spaces due to birth trauma complications (e.g. cephalohematoma) * Suspected or documented neonatal infection such as chorioamnionitis, intrauterine infection, sepsis and urinary tract infection * Perinatal and neonatal hypoxia * Having thyroid dysfunction, respiratory distress or insufficiency, metabolic and thermoregulatory dysfunction, hemodynamic instability and congenital heart disease * Maternal phenobarbital usage history during the last month of the pregnancy * Having venous hematocrit (Htc) levels≥65%

Outcomes

Primary Outcomes

Effect of Probiotic Support on Serum Bilirubin Levels

The effect of probiotic support on serum bilirubin levels during the first 10 days were measured and results were given as mg/dL.

Time frame: Change from birth to ten days of life

Secondary Outcomes

Defecation frequency

Number of defecation frequency releated to treatment was evaluated and counted as times/a day.

Time frame: Change from birth to ten days of life

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.